Patents Represented by Attorney, Agent or Law Firm Henry D. Coleman
  • Patent number: 8263591
    Abstract: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: September 11, 2012
    Assignee: Cortex Pharmaceuticals, Inc.
    Inventors: Rudolf Mueller, Leslie Street
  • Patent number: 8263556
    Abstract: The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: September 11, 2012
    Assignee: STC.UNM
    Inventors: Terry W. Du Clos, Carolyn Mold
  • Patent number: 8247371
    Abstract: The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and/or an antibody against claudin-4.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: August 21, 2012
    Assignee: Yale University
    Inventors: Alessandro D. Santin, Fabrizio Comper
  • Patent number: 8242120
    Abstract: The present invention relates to the use of carbodine and 5-F carbodine and analogs thereof for use in the treatment or prophylaxis of influenza, in particular the H5N1 strain of Avian Influenza A virus or “bird flu” strain of influenza as well as the treatment or prophylaxis of Venezuela equine encephalitis virus or VEE.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: August 14, 2012
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: David Chu, Jagadeeshwar Rao
  • Patent number: 8207143
    Abstract: The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each R8 is independently H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: June 26, 2012
    Assignee: Yale University
    Inventor: Yung-chi Cheng
  • Patent number: 8193165
    Abstract: The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: June 5, 2012
    Assignee: Yale University
    Inventors: Yung-chi Cheng, Hiromichi Tanaka, Masanori Baba
  • Patent number: 8178089
    Abstract: The present invention relates to methods for producing feeder cell-free neuroprogenitor cells (preferably adherent) from embryonic stems cells, preferably human embryonic stem cells, the feeder cell-free neuroprogenitor cells, preferably human cells themselves, as well as methods for producing feeder cell-free samples of neuronal cells, preferably adherent human neuronal cells and the feeder cell-free neuronal cells themselves. Pharmaceutical compositions and methods of treating neurodegenerative diseases as well as the use of the described cells in assay systems is also described.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: May 15, 2012
    Assignee: The University of Georgia Research Foundation, Inc
    Inventors: Steve Stice, Soojung Shin, Sujoy Dhara
  • Patent number: 8168657
    Abstract: The present invention relates to solenopsin A and its analogs for use as angiogenesis inhibitors. The present compounds unexpectedly exhibit good activity as angiogenesis inhibitors, which find use as antitumor/anticancer agents as well as to treat a number of conditions or disease states in which angiogenesis is a factor.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: May 1, 2012
    Inventors: J. Phillip Bowen, Jack L. Arbiser, David Whitmire, M. Scott Furness
  • Patent number: 8168632
    Abstract: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: May 1, 2012
    Assignee: Cortex Pharmaceuticals, Inc.
    Inventors: Rudolf Mueller, Leslie J. Street
  • Patent number: 8119632
    Abstract: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: February 21, 2012
    Assignee: Cortex Pharmaceuticals, Inc.
    Inventors: Rudolf Mueller, Leslie J. Street
  • Patent number: 8114987
    Abstract: A method of preparing 2-deoxy-L-ribose represented by the following formula I is disclosed. The preparation method includes the steps of: treating L-arabinose with an alcohol solvent in the presence of an acid to prepare 1-alkoxy-L-arabinopyranose; allowing the prepared 1-alkoxy-L-arabinopyranose to react with acyl chloride so as to prepare 1-alkoxy-2,3,4-triacyl-L-arabinopyranose; brominating the alkoxy group of the prepared 1-alkoxy-2,3,4-triacyl-L-arabinopyranose to prepare a 1-bromo-2,3,4-triacyl compound; allowing the prepared compound to react with zinc in the presence of ethyl acetate and an organic base so as to prepare glycal; treating the glycal with an alcohol solvent in the presence of an acid to prepare 1-alkoxy-2-deoxy-3,4-diacyl-L-ribopyranose; treating the prepared 1-alkoxy-2-deoxy-3,4-diacyl-L-ribopyranose with a base to prepare 1-alkoxy-2-deoxy-L-ribopyranose; and hydrolyzing the prepared 1-alkoxy-2-deoxy-L-ribopyranose in the presence of an acid catalyst.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: February 14, 2012
    Assignee: Samchully Pharm. Co. Ltd.
    Inventors: Kyung-Il Kim, Seung-Bum Ha, Jae-Hoon Jeon, Soon-Jeong Kwon, Yong-Tae Kim, Ji-Suk Yun
  • Patent number: 8110584
    Abstract: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: February 7, 2012
    Assignee: Cotex Pharmaceuticals, Inc.
    Inventors: Rudolf Mueller, Leslie Street
  • Patent number: 8101213
    Abstract: The present invention provides compositions comprising an effective amount of xanthohumol and honokiol. The present invention comprises compositions comprising an effective amount of xanthohumol and genistein. The present invention comprises compositions comprising an effective amount of xanthohumol and guggulsterone. The compositions of the present invention may be effective to decrease mature adipocytes viability, induce apoptosis of mature adipocytes, increase lipolysis in mature adipocytes, and/or reduce adipogenesis during the maturation of pre-adipocytes. The present invention further provides methods of treating obesity, diabetes, osteoporosis or bone disorders in a subject, which comprise administering to the subject compositions comprising an effective amount of xanthohumol and honokiol, guggulsterone, or genistein.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: January 24, 2012
    Assignee: The University of Georgia Research Foundation, Inc
    Inventors: Clifton A. Baile, Mary Anne Della-Fera, Jeong-Yeh Yang, Srujana Rayalam, Hea Jin Park
  • Patent number: 8101714
    Abstract: The invention is directed to an isolated polypeptide which (a) is obtainable from a teleost; (b) has antimicrobial activity; (c) binds to oligoguanosine and/or CpG (SEQ ID NO:7); (d) comprises 58 strongly basic amino acids selected from the group consisting of K and R; (e) comprises 50 hydrophobic amino acids selected from the group consisting of A, I, L, F, W and V; (f) comprises 50 polar amino acids selected from the group consisting of N, C, Q, S, T and Y and (g) contains 11 lysine-rich motifs and antimicrobial fragments thereof as well as methods for preparing said polypeptides, compositions and libraries comprising said polypeptide(s) and uses of said polypeptide(s), particularly in treating microbial infections. The invention is further directed to a nucleic acid(s) encoding said polypeptide, microarrays comprising said nucleic acid(s) and uses for said nucleic acid(s).
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: January 24, 2012
    Assignee: The University of Georgia Research Foundation, Inc.
    Inventors: Donald L. Evans, Harjeet Kaur, Liliana Jaso-Friedmann, John H. Leary, III, Kesavannair Praveen
  • Patent number: 8097237
    Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: January 17, 2012
    Assignee: STC.UNM
    Inventors: Jeffrey P. Norenberg, Richard S. Larson
  • Patent number: 8084471
    Abstract: The present invention relates to compounds, pharmaceutical compositions and methods which inhibit the binding of coactivator proteins in nuclear receptors, including estrogen receptors (alpha and/or beta), androgen receptors, thyroid receptors and peroxisome proliferators-activated receptors, among others. Compounds according to the present invention may be useful in the treatment of a variety of disease states or conditions which are mediated through nuclear receptors.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: December 27, 2011
    Assignee: Yale University
    Inventors: Andrew Hamilton, Jorge Becerril
  • Patent number: 8084641
    Abstract: The present invention is directed to compositions comprising organocatalysts that facilitate stereo-selective reactions and the method of their synthesis and use. Particularly, the invention relates to metal-free organocatalysts for facilitation of stereo-selective reactions, and the method of their synthesis and use.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: December 27, 2011
    Assignee: STC.UNM
    Inventor: Wei Wang
  • Patent number: 8076347
    Abstract: (?)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (?)-OddC) or its derivative and its use to treat cancer in animals, including humans.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: December 13, 2011
    Assignees: University of Georgia Research Foundation, Inc., Yale University
    Inventors: Chung K. Chu, Yung-chi Cheng
  • Patent number: 8013120
    Abstract: The present invention relates to the use of C-reactive protein, its mutants, metabolites and polypeptides and related compounds thereof for the treatment of various disease states and conditions associated with systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein, hi another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition with systemic lupus erythematosus will have an outbreak is an additional aspect of the present invention.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: September 6, 2011
    Assignee: STC.UNM
    Inventors: Terry W. Du Clos, Carolyn Mold
  • Patent number: 8013003
    Abstract: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: September 6, 2011
    Assignee: Cortex Pharmaceuticals, Inc.
    Inventors: Leslie Street, Rudolf Mueller, Steven Lee